International patent applications on ATX and ATX inhibitors
4-(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)
Espacenet: WO2024134227A1
PCT International Application WO 2024/134227 A1; Inventors: Vassilios Aidinis and Alexios Matralis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Priority 22-12-2022 • Filing 20-12-2023 • Publication 27-06-2024.
The present invention relates to a pharmaceutical compound or pharmaceutically acceptable salt thereof, for use in the prevention or the treatment of a) fibro-proliferative diseases, in particular interstitial lung diseases (ILD) and/or liver diseases, such as all forms of hepatitis and/or non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) and/or cirrhosis, wherein said ILD being either primary disease, preferably idiopathic pulmonary fibrosis and/or sarcoidosis and/or interstitial pneumonias or said ILD being comorbid to autoimmune and/or inflammatory and/or metabolic diseases, preferably rheumatoid arthritis-ILD and/or scleroderma-ILD and/or myositis-ILD and/or diabetes-ILD and/or cardiovascular diseases-ILD and/or b) inflammatory diseases and/or autoimmune diseases, preferably rheumatoid arthritis and/or scleroderma and/or c) cancer, in particular lung cancer and/or hepatocellular carcinoma and/or pancreatic cancer and/or glioblastoma and/or neuroblastoma and/or d) metabolic diseases, in particular diabetes type I and/or diabetes type II and/or obesity, due to simultaneous Autotaxin (ATX) inhibition and PPARy agonism.
Thieno[3,4-c]pyrazol-3-yl acetamides
Espacenet: WO2022003377A1
PCT International Application WO 2022/003377 A1; Inventors: Vassilios Aidinis and Alexios Matralis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Priority 2020-07-02 • Filing 2021-07-02 • Publication 2022-01-07. Pending.
A pharmaceutical compound or pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary fibrosis, pulmonary allograft fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis, pneumonia, COVID-19 disease, bacterial infection, rheumatoid arthritis, neurodegenerative diseases, diseases related to metabolic syndrome and cancer, due to autotaxin inhibition.
Autotaxin pathway modulation and uses thereof.
EP US WO Application WO2011151461A2 Vassilios Aidinis B.S.R.C. "Alexander Fleming". Priority 2010-06-04 • Filing 2011-06-03 • Publication 2011-12-08. Aborted
Disclosed are methods for preventing, treating, or reducing symptoms of a disorder involving the autotaxin (ATX) pathway. In one embodiment, the method features administering to a mammal a sufficient amount of an autotaxin (ATX) or lysophosphatidic acid (LPA) signaling inhibitor, to prevent, treat or reduce symptoms of an inflammatory disorder, autoimmune disorder, fibrosis or malignancy of the lung. Further disclosed are methods for diagnosing an autotaxin-related disorder as well as kits for performing the methods of the invention.
Deregulated Genes and/or Processes in Inflammatory Arthritis.
EP JP US WO Application US20080311185A1 Georgios Kollias, Vassilios Aidinis, Yoshishide Hayashizaki, Piero Carninci. Priority 2005-10-19 • Filing 2006-10-19 • Publication 2008-12-18. Aborted
The invention provides means and methods for determining whether a sample is derived from an individual suffering from inflammatory arthritis or from an individual at risk of suffering there from, said method comprising measuring in said sample the level of expression of at least one gene product of a gene of table A, table B or and comparing said expression level with a reference value. Further provided is a non-human animal model comprising an altered expression of a gene of table A, table B or when compared to a reference non-human animal, and use of this model as or in an arthritis model. Further provided is an in vitro assay for screening compounds for effect on a phenotype of synovial fibroblasts. The synovial fibroblast are preferably derived from a human or non-human animal suffering from inflammatory arthritis.
Granted local patents on ATX inhibitors
4-(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)
Espacenet: GR1010570B
Hellenic Industrial Property Organisation number 1010570, date of granting 11/12/2023. Inventors: Vassilios Aidinis and Alexios Matralis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Thieno[3,4-c]pyrazol-3-yl acetamides
Espacenet: GR1010099B
Hellenic Industrial Property Organisation number 1010099, date of granting 08/10/2021. Inventors: Vassilios Aidinis and Alexios Matralis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Espacenet: GR1010098B
Hellenic Industrial Property Organisation number 1010098, date of granting 08/10/2021. Inventors: Vassilios Aidinis and George Kokotos; Owners: B.S.R.C. "Alexander Fleming", Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. and National and Kapodistrian University of Athens.
Tetrahydro-2-benzo(b)thiophene-1-carboxylic esters
Espacenet: GR1010104B
Hellenic Industrial Property Organisation number 1010104, date of granting 18/10/2021. Inventor: Vassilios Aidinis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
3-indol-2-ylmethylidene-indolin-2-ones
Espacenet: GR1010103B
Hellenic Industrial Property Organisation number 1010103, date of granting 18/10/2021. Inventor: Vassilios Aidinis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Pyrrolo[1,2-a]pyrazino-2(1H)-thiocarbamides
Espacenet: GR1010097B
Hellenic Industrial Property Organisation number 1010097, date of granting 08/10/2021. Inventor: Vassilios Aidinis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Espacenet: GR1010096B
Hellenic Industrial Property Organisation number 1010096, date of granting 08/10/2021. Inventor: Vassilios Aidinis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
N-[2-(4-bromophenyl)-2,5-dihydro-4H-thieno[3,4-C]pyrazol-3-yl-acetamides
Espacenet: GR1010268B
Hellenic Industrial Property Organisation number 1010268, date of granting 20/07/2022. Inventors: Vassilios Aidinis and Alexios Matralis; Owners: B.S.R.C. "Alexander Fleming" and Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.